Section 4: Clinical Pharmacy Services 2019 Help me understand this report
4CPS-128 Adequacy of nivolumab and pembrolizumab in non-small-cell lung cancer
Abstract: Number of chronic medications >6 1Ambulatory high-risk drug 2High-emetic risk chemotherapy 1Oral antineoplastic agent Highest priority Clinical variablesGastrointestinal tumour 1 Chronic diseases 2Treatment line >1 1
This publication either has no citations yet, or we are still processing them
Set email alert for when this publication receives citations?
See others like this or search for similar articles
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
